SER109

Unassigned

New Medicines

Clostridium difficile infection - prevention of recurrence

Information

Bacterial replacement
Nestle Health Science
Seres Therapeutics

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Bacteria replacement. An oral capsule containing spores from bacteria isolated from stool samples.
PHS England reports indicate an overall C. diff infection rate in English hospital Trusts of 41 per 100,000 bed days (14,165 reports) for FY 2014-15; total CCG attributed rate for specimens for the same year was 26.3 per 100,000 [2].
Clostridium difficile infection - prevention of recurrence
Oral